CCL27 and inflammatory bowel disease: This plasticity is further illustrated in IBD, where modulation of cytokine networks (e.g., anti-IL-12/23 ustekinumab) partially restores ILC subset balance and shifts pro-inflammatory ILC1/ILC3 populations toward a more homeostatic profile (130).